Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Brief Summary: This is a randomized, open label, multicenter phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immunochemotherapy.


Options:
A: Arm Label: HIGH DOSE CHEMOTHERAPY AND ASCT; Type: EXPERIMENTAL; Interventions: Drug: Carmustine, Drug: Etoposide, Drug: Cytarabine, Drug: Melphalan, Biological: Pegfilgrastim, Biological: 19-28z T CELLS, Procedure: Autologous Stem Cell Transplantation | Intervention Type: DRUG; Name: Carmustine; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: DRUG; Name: Cytarabine; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: BIOLOGICAL; Name: Pegfilgrastim; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: BIOLOGICAL; Name: 19-28z T CELLS; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT | Intervention Type: PROCEDURE; Name: Autologous Stem Cell Transplantation; Assigned to Arm(s): HIGH DOSE CHEMOTHERAPY AND ASCT
B: Arm Label: CAR T cells; Type: EXPERIMENTAL; Interventions: Biological: Autologous 3rd generation CD19-targeting CAR T cells | Intervention Type: BIOLOGICAL; Name: Autologous 3rd generation CD19-targeting CAR T cells; Assigned to Arm(s): CAR T cells
C: Arm Label: Tisagenlecleucel treatment strategy; Type: EXPERIMENTAL; Interventions: Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy | Arm Label: Standard of care treatment strategy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT) | Intervention Type: DRUG; Name: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy; Assigned to Arm(s): Tisagenlecleucel treatment strategy | Intervention Type: DRUG; Name: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT); Assigned to Arm(s): Standard of care treatment strategy
D: Arm Label: Axicabtagene Ciloleucel and Rituximab Combination; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Rituximab, Drug: Fludarabine, Drug: Cyclophosphamide | Intervention Type: BIOLOGICAL; Name: Axicabtagene Ciloleucel; Assigned to Arm(s): Axicabtagene Ciloleucel and Rituximab Combination | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Axicabtagene Ciloleucel and Rituximab Combination | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): Axicabtagene Ciloleucel and Rituximab Combination | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Axicabtagene Ciloleucel and Rituximab Combination

Answer: C